Schedule 13G ownership disclosure

UROGEN PHARMA LTD

Ordinary Shares, par value NIS 0.01 per share · CUSIP: M96088105

Event date: 2025-06-13

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Soleus Capital Master Fund, L.P.

    Shares: 2,325,000.00 · Class: 5.0%

  • Soleus Capital, LLC

    Shares: 2,325,000.00 · Class: 5.0%

  • Soleus Capital Group, LLC

    Shares: 2,325,000.00 · Class: 5.0%

  • Soleus Capital Management, L.P.

    Shares: 2,325,000.00 · Class: 5.0%

  • Soleus GP, LLC

    Shares: 2,325,000.00 · Class: 5.0%

  • Guy Levy

    Shares: 2,325,000.00 · Class: 5.0%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-25-054819
Form type
SCHEDULE 13G
Filer
Soleus Capital Master Fund, L.P.
CIK
CIK 1812275
Filed
Jun 16, 2025
Reporting period
Jun 13, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub